Literature DB >> 26748493

Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta-Analysis.

Vinayak Nagaraja1, Senarath Edirimanne1, Guy D Eslick1.   

Abstract

The gain by performing sentinel lymph node biopsy (SLNB) during prophylactic mastectomy (PM) is debatable, and we performed a meta-analysis of existing literature to evaluate that the role of SLNB in subjects undergoing PM. A systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane library, Google Scholar, Science Direct, and Web of Science. The search identified 11 relevant articles reporting on patients who underwent SLNB at the time of PM. Data were abstracted from each study and used to calculate a pooled odds ratio (OR) and 95% confidence interval (95% CI). We included 14 studies comprising of 2,708 prophylactic mastectomies. Among 2,708 prophylactic mastectomies, the frequency of occult invasive cancer (51 cases) was 1.8% and the rate of positive SLNs (33 cases) was 1.2%. In 25 invasive cancers at the time of PM were found to have negative SLNs which avoided axillary lymph node dissection (ALND). In seven cases with positive SLNBs were found not to have invasive cancer at the time of PM and needed a subsequent ALND. Most of the patients with positive SLNs had locally advanced disease in the contralateral breast. SLNB may be suitable for patients with ipsilateral, locally advanced breast cancer and is not recommend for all patients undergoing PM.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; prophylactic mastectomy; sentinel lymph node biopsy

Mesh:

Year:  2016        PMID: 26748493     DOI: 10.1111/tbj.12549

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  4 in total

1.  The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.

Authors:  Sara Câmara; Daniela Pereira; Saudade André; Beatriz Mira; Fátima Vaz; Rodrigo Oom; José Carlos Marques; João Leal de Faria; Catarina Rodrigues Dos Santos
Journal:  Int J Breast Cancer       Date:  2018-01-01

2.  Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making.

Authors:  Judy C Boughey; Deanna J Attai; Steven L Chen; Hiram S Cody; Jill R Dietz; Sheldon M Feldman; Caprice C Greenberg; Rena B Kass; Jeffrey Landercasper; Valerie Lemaine; Fiona MacNeill; Julie A Margenthaler; David H Song; Alicia C Staley; Lee G Wilke; Shawna C Willey; Katharine A Yao
Journal:  Ann Surg Oncol       Date:  2016-07-28       Impact factor: 5.344

Review 3.  Sentinel Lymph Node Biopsy in Breast Cancer: A Clinical Review and Update.

Authors:  Sheikh Zahoor; Altaf Haji; Azhar Battoo; Mariya Qurieshi; Wahid Mir; Mudasir Shah
Journal:  J Breast Cancer       Date:  2017-09-22       Impact factor: 3.588

Review 4.  Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy.

Authors:  Walter P Weber; Martin Haug; Christian Kurzeder; Vesna Bjelic-Radisic; Rupert Koller; Roland Reitsamer; Florian Fitzal; Jorge Biazus; Fabricio Brenelli; Cicero Urban; Régis Resende Paulinelli; Jens-Uwe Blohmer; Jörg Heil; Jürgen Hoffmann; Zoltan Matrai; Giuseppe Catanuto; Viviana Galimberti; Oreste Gentilini; Mitchel Barry; Tal Hadar; Tanir M Allweis; Oded Olsha; Maria João Cardoso; Pedro F Gouveia; Isabel T Rubio; Jana de Boniface; Tor Svensjö; Susanne Bucher; Peter Dubsky; Jian Farhadi; Mathias K Fehr; Ilario Fulco; Ursula Ganz-Blättler; Andreas Günthert; Yves Harder; Nik Hauser; Elisabeth A Kappos; Michael Knauer; Julia Landin; Robert Mechera; Francesco Meani; Giacomo Montagna; Mathilde Ritter; Ramon Saccilotto; Fabienne D Schwab; Daniel Steffens; Christoph Tausch; Jasmin Zeindler; Savas D Soysal; Visnu Lohsiriwat; Tibor Kovacs; Anne Tansley; Lynda Wyld; Laszlo Romics; Mahmoud El-Tamer; Andrea L Pusic; Virgilio Sacchini; Michael Gnant
Journal:  Breast Cancer Res Treat       Date:  2018-09-04       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.